Opus Genetics reports Phase I/II trial results of OPGx-BEST1 gene therapy

Phase 1positiveOPGx-BEST1Positive

AI Analysis

Summary

Opus Genetics reported early Phase I/II trial results for OPGx-BEST1 gene therapy targeting BVMD and ARB. Limited detail available on efficacy or safety outcomes.

Clinical Trial Data

Phase

Phase I/II

Outcome Details

Early findings reported from Phase I/II trial

Importance:5/10

Sentiment:

0.60

gene therapyBVMDARBearly stageophthalmology

Related Companies

$ARNA $FCHS

Read the original article

Published by Clinical Trials Arena on March 2, 2026 9:28 AM

Read Original